Nicholas G Zaorsky1, Scott W Keith2, Talha Shaikh1, Paul L Nguyen3, Eric M Horwitz1, Adam P Dicker4, Robert B Den4. 1. Department of Radiation Oncology, Fox Chase Cancer Center. 2. Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics. 3. Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA. 4. Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.
Abstract
OBJECTIVES: Freedom from biochemical failure (FFBF) is a common primary outcome of randomized-controlled trials of prostate cancer (PCa). We aimed to determine how increasing the PCa biologically equivalent dose (BED) of external radiation therapy (RT) is correlated with FFBF and overall patient outcomes: overall survival (OS), distant metastasis (DM), and cancer-specific mortality (CSM); as well as genitourinary (GU), and gastrointestinal toxicities. MATERIALS AND METHODS: We performed a meta-analysis of 6884 PCa patients from 12 randomized-controlled trials of external beam RT. Mixed effects regression models were used to estimate weighted linear relationships between BED and observed percentages of 5- and 10-year outcomes. For toxicities, a subset analysis of using 3-dimensional conformal RT (3D-CRT) versus intensity-modulated RT (IMRT) was performed. RESULTS: Increasing BED correlated with improved FFBF: 10-year absolute improvement of 9.6% and 7.2% for low-risk and intermediate-risk patients, respectively (P<0.05); but not with improvement of OS, DM, or CSM at either time point. BED escalation was not correlated with increased acute toxicities; it was correlated with increased late gastrointestinal toxicities in patients treated with 3D-CRT (1.5% increase over BED range, P<0.01). IMRT patients had significantly fewer late toxicities, despite being treated at higher BED. CONCLUSIONS: RT BED escalation has resulted in significantly improved PCa FFBF at up to 10 years; but not with improvement in OS, DM, or CSM. Thus, FFBF is a poor surrogate of overall patient outcomes for trials of RT. Late toxicities were less frequent with IMRT than with 3D-CRT, even at higher BED.
OBJECTIVES: Freedom from biochemical failure (FFBF) is a common primary outcome of randomized-controlled trials of prostate cancer (PCa). We aimed to determine how increasing the PCa biologically equivalent dose (BED) of external radiation therapy (RT) is correlated with FFBF and overall patient outcomes: overall survival (OS), distant metastasis (DM), and cancer-specific mortality (CSM); as well as genitourinary (GU), and gastrointestinal toxicities. MATERIALS AND METHODS: We performed a meta-analysis of 6884 PCa patients from 12 randomized-controlled trials of external beam RT. Mixed effects regression models were used to estimate weighted linear relationships between BED and observed percentages of 5- and 10-year outcomes. For toxicities, a subset analysis of using 3-dimensional conformal RT (3D-CRT) versus intensity-modulated RT (IMRT) was performed. RESULTS: Increasing BED correlated with improved FFBF: 10-year absolute improvement of 9.6% and 7.2% for low-risk and intermediate-risk patients, respectively (P<0.05); but not with improvement of OS, DM, or CSM at either time point. BED escalation was not correlated with increased acute toxicities; it was correlated with increased late gastrointestinal toxicities in patients treated with 3D-CRT (1.5% increase over BED range, P<0.01). IMRT patients had significantly fewer late toxicities, despite being treated at higher BED. CONCLUSIONS: RT BED escalation has resulted in significantly improved PCa FFBF at up to 10 years; but not with improvement in OS, DM, or CSM. Thus, FFBF is a poor surrogate of overall patient outcomes for trials of RT. Late toxicities were less frequent with IMRT than with 3D-CRT, even at higher BED.
Authors: Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz Journal: Nat Rev Urol Date: 2017-06-30 Impact factor: 14.432
Authors: Nicholas G Zaorsky; Charles T Lee; Eddie Zhang; Scott W Keith; Thomas J Galloway Journal: Radiother Oncol Date: 2017-08-23 Impact factor: 6.280
Authors: Nicholas G Zaorsky; Thomas M Churilla; Karen Ruth; Shelly B Hayes; Mark L Sobczak; Mark A Hallman; Marc C Smaldone; David Yt Chen; Eric M Horwitz Journal: Am J Clin Nutr Date: 2016-10-26 Impact factor: 7.045
Authors: Yanqun Dong; Nicholas G Zaorsky; Tianyu Li; Thomas M Churilla; Rosalia Viterbo; Mark L Sobczak; Marc C Smaldone; David Yt Chen; Robert G Uzzo; Mark A Hallman; Eric M Horwitz Journal: J Med Imaging Radiat Oncol Date: 2017-10-13 Impact factor: 1.735
Authors: Nicholas G Zaorsky; Talha Shaikh; Karen Ruth; Pankaj Sharda; Shelly B Hayes; Mark L Sobczak; Mark A Hallman; Marc C Smaldone; David Y T Chen; Eric M Horwitz Journal: Clin Genitourin Cancer Date: 2016-09-08 Impact factor: 2.872
Authors: William A Hall; Snehal Deshmukh; Deborah W Bruner; Jeff M Michalski; James A Purdy; Walter Bosch; Jean-Paul Bahary; Maltibehn P Patel; Matthew B Parliament; Michael I Lock; Harold Y Lau; Luis Souhami; Scot A Fisher; Young Kwok; Michael J Seider; Eric Vigneault; Seth A Rosenthal; Gary S Gustafson; Hiram A Gay; Stephanie L Pugh; Howard M Sandler; Benjamin Movsas Journal: Int J Radiat Oncol Biol Phys Date: 2022-01-01 Impact factor: 7.038